FBRX_OUT_1 [2025-04-16 16:17:41 -0400] 4229 Bytes | 1235 tokens | Cum: 1235 tkns (15.44% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Forte Biosciences (FBRX) which is at 7.2600 up from 5.8400. So, I pulled together a bunch of data for you to look over real fast. It's still early, 4:17:40 PM on Wed Apr 16, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Forte Biosciences (FBRX)
IPO: 2020-06-16 (4 Years Ago)
Market Cap: $47,502,390
Shares Outstanding: 6,390,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).

Here’s a list of headlines for Forte Biosciences:

Apr-03-25 12:00PM - All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Mar-31-25 09:00AM - Forte Biosciences, Inc. Announces Results and Provides Clinical Update
Feb-03-25 09:00AM - Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
Nov-25-24 09:00AM - Forte Biosciences to Host RandD Day December 3, 2024
Nov-25-24 09:00AM 09:00AM - Forte Biosciences to Host R&D Day December 3, 2024
Nov-20-24 09:00AM - Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Nov-14-24 04:01PM - Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
Aug-26-24 11:51AM - Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested

Prior AI Reports for FBRX:
1. 2025-03-25 – Score: 25 – Target: 8.3100 – Highs: 8.9900 / 9.0775 / 8.87
forte-biosciences-sees-insider-trading-amid-negative-performance
2. 2025-03-20 – Score: 45 – Target: 10.0000 – Highs: 8.8600 / 8.9500 / 9.33
forte-biosciences-challenging-times-but-insider-confidence-surfaces
3. 2025-03-19 – Score: 50 – Target: 6.5000 – Highs: 7.4800 / 8.8600 / 8.95
forte-biosciences-fights-against-negative-profitability-trend

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-03-25T16:00:10Z - What Makes Forte Biosciences (FBRX) a New Buy Stock
B2 - 2023-12-13T13:29:24Z - Research Frontiers And 3 Other Stocks Under $1 Insiders Are Buying
B3 - 2023-12-11T13:34:01Z - RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
B4 - 2023-11-24T11:38:00Z - Insiders Buying Vintage Wine Estates And 3 Other Stocks Under $1
B5 - 2023-04-06T19:53:22Z - Penny Stocks To Buy Now? 4 To Watch In April
B6 - 2022-07-13T08:59:07Z - Boeing, PriceSmart And 80 Biggest Movers From Yesterday

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Forte Biosciences (FBRX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

FBRX_OUT_3 [2025-04-16 16:17:46 -0400] 629 Bytes | 181 tokens | Cum: 1418 tkns (17.72% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**What Makes Forte Biosciences (FBRX) a New Buy Stock**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2245625/what-makes-forte-biosciences-fbrx-a-new-buy-stockForte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_5 [2025-04-16 16:17:47 -0400] 960 Bytes | 289 tokens | Cum: 1709 tkns (21.36% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-07T21:05:55Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Bluejay Diagnostics (NASDAQ:BJDX), A...
A2 - 2025-04-01T10:51:06Z - Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?...
A3 - 2025-03-28T11:03:20Z - North American Morning Briefing: Tariff Jitters -2-...
A4 - 2025-03-25T17:05:55Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - CNS Pharma (NASDAQ:CNSP), IMAC Hldgs (N...
A5 - 2025-03-21T10:49:49Z - North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

FBRX_OUT_7 [2025-04-16 16:17:48 -0400] 1181 Bytes | 357 tokens | Cum: 2068 tkns (25.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - Bluejay Diagnostics (NASDAQ:BJDX), Agilon Health (NYSE:AGL)**Date: 2025-04-07Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44675169/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers Agilon Health AGL stock moved upwards by 17.2% to $4.98 during Monday's after-market session. The market value of their outstanding shares is at $2.0 billion. Humana HUM stock moved upwards by 14.64% to $292.0. The market value of their outstanding shares is at $35.2 billion. RenovoRx RNXT stock rose 13.7% to $0.9. The company's market cap stands at $31.9 million. Pacira BioSciences PCRX stock moved upwards by 13.48% to $26.0. The market value of their outstanding shares is at $1.2 billion. DIH Holding US DHAI stock moved upwards by 9.76% to $0.1

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_9 [2025-04-16 16:17:48 -0400] 1181 Bytes | 350 tokens | Cum: 2420 tkns (30.25% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): 9. The company's market cap stands at $8.9 million. Oragenics OGEN shares moved upwards by 9.19% to $0.19. The company's market cap stands at $4.0 million. Losers Shattuck Labs STTK stock fell 19.2% to $1.05 during Monday's after-market session. The market value of their outstanding shares is at $50.3 million. CVRx CVRX stock fell 14.22% to $9.9. The market value of their outstanding shares is at $257.7 million. Entero Therapeutics ENTO shares declined by 13.92% to $0.42. The company's market cap stands at $2.0 million. Forte Biosciences FBRX stock decreased by 13.68% to $4.61. The market value of their outstanding shares is at $29.4 million. TNF Pharmaceuticals TNFA shares declined by 11.78% to $0.32. Bluejay Diagnostics BJDX stock decreased by 10.14% to $6.74. The market value of their outstanding shares is at $3.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_11 [2025-04-16 16:17:49 -0400] 1025 Bytes | 345 tokens | Cum: 2767 tkns (34.59% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): article was generated by Benzinga's automated content engine and reviewed by an editor.

AGLAgilon Health Inc$4.8516.9%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum85.79Growth80.96Quality-Value62.78Price TrendShortMediumLongOverviewBJDXBluejay Diagnostics Inc$6.7190.1%CVRXCVRx Inc$10.50-10.4%DHAIDIH Holding US Inc$0.200010.3%ENTOEntero Therapeutics Inc$0.4514-11.3%FBRXForte Biosciences Inc$4.56-22.4%HUMHumana Inc$286.4012.9%OGENOragenics Inc$0.19001.50%PCRXPacira BioSciences Inc$26.9616.7%RNXTRenovoRx Inc$0.89821.91%STTKShattuck Labs Inc$1.1151.4%TNFATNF Pharmaceuticals Inc$0.3392-8.55%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_13 [2025-04-16 16:17:50 -0400] 509 Bytes | 118 tokens | Cum: 2887 tkns (36.09% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S3 - 2025-03-28 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the CONS financial statements and the related no...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

FBRX_OUT_15 [2025-04-16 16:17:51 -0400] 1181 Bytes | 259 tokens | Cum: 3148 tkns (39.35% of 8k)
==========================================================================

Showing S3 (chunk 1 of 6): S3:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes contained elsewhere in this Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. The known risks and uncertainties include, but are not limited to, those identified and described in detail under the caption Risk Factors and elsewhere in this Form 10-K.

Overview

Forte Biosciences, Inc. and its subsidiaries ( www.fortebiorx.com ) (Forte, we, our) is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102. FB102 is a proprietary anti-CD122 monoclonal antib

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_17 [2025-04-16 16:17:52 -0400] 1181 Bytes | 266 tokens | Cum: 3416 tkns (42.70% of 8k)
==========================================================================

Showing S3 (chunk 2 of 6): ody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Our FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets.

In FB102 mechanistic in-vitro studies, human donor T and NK cells were stimulated with either IL2 or IL15 in the presence or absence of FB102. FB102 significantly inhibited proliferation (4-5x inhibition in the proliferation of T cells and 6-8 fold inhibition in the proliferation of NK cells) and also inhibited activation of T cells. The level of FB102 inhibition of proliferation and activation was at levels comparable to unstimulated cells. Human donor regulatory T cell (Treg) studies stimulated with IL2 demonstrated comparable proliferation both in the presence and absence of FB1

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_19 [2025-04-16 16:17:53 -0400] 1181 Bytes | 269 tokens | Cum: 3687 tkns (46.09% of 8k)
==========================================================================

Showing S3 (chunk 3 of 6): 02. Additionally, in-vitro assays demonstrated superiority of FB102 compared to competing antibodies.

In the 4- and 13-week non-human primate (NHP) studies, after a single dose, FB102 demonstrated significant reductions in the NK cell pharmacodynamic marker (up to approximately 80%-90%). Additionally, after multiple doses at exposures comparable to human therapeutic doses, Treg levels in the FB102 dosing arm were similar to vehicle supporting the in-vitro data and the mechanism of action of FB102.

Three cohorts of single and two cohorts of multiple ascending doses in a Phase 1 trial of healthy volunteers were completed in which FB102 demonstrated a good safety profile. The primary objective of the Phase 1 trial was to assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of FB102. No dose limiting toxicities were observed. FB102 demonstrated sign

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_21 [2025-04-16 16:17:54 -0400] 1181 Bytes | 277 tokens | Cum: 3966 tkns (49.58% of 8k)
==========================================================================

Showing S3 (chunk 4 of 6): ificant reductions in the NK cell pharmacodynamic marker (greater than approximately 70%). Based on the successful completion of the phase 1 healthy volunteer cohorts, we initiated a patient-based trial in celiac disease in the third quarter of 2024. The study is currently enrolling and top-line results are expected in the second quarter of 2025.

Celiac disease is an autoimmune disease that is triggered by consuming gluten and results in damage to the small intestine. Symptoms include diarrhea, fatigue, headaches, anemia, nausea and dermatitis herpetiformis (an itchy skin rash). A significant patient population of celiac disease patients do not respond to gluten free diet. The health consequences for not treating include malnourishment, cancer, other autoimmune conditions. It is estimated that 1:133 in US (2.5 million people) have celiac disease (Fasano, Arch Intern Med. 2003 PMID: 125

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_23 [2025-04-16 16:17:55 -0400] 1181 Bytes | 310 tokens | Cum: 4278 tkns (53.47% of 8k)
==========================================================================

Showing S3 (chunk 5 of 6): 78508) and that 0.3% to 0.5% of celiac disease patients are non-responsive (Malamut Gastroenterology. 2024 38556189). There are no approved treatment options for celiac disease.

FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata and type 1 diabetes (T1D).

Vitiligo is a disease of the skin mediated primarily by NK and CD8+ T cells that attack melanocytes leading to patchy depigmentation of the skin. It is estimated that vitiligo affects 2 million people in the U.S (NIH). The global vitiligo treatment market size was estimated at $1.2 billion in 2018 and is projected to reach $1.9 billion by 2026 (Fortune Business Insights).

Alopecia areata is a disease in which immune cells attack and damage hair follicles and is mediated primarily by CD8+ T cells and NK cells. The global alopecia treatment market was valued at $2.7 billion

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_25 [2025-04-16 16:17:57 -0400] 790 Bytes | 223 tokens | Cum: 4503 tkns (56.29% of 8k)
==========================================================================

Showing S3 (chunk 6 of 6): in 2018, and is projected to reach $3.9 billion by 2026, registering a CAGR of 4.6% from 2019 to 2026 (Allied Mkt Research).

Type 1 diabetes is caused by autoreactive T Cells destroying insulin-producing pancreatic - cells. CD8+ T cells with receptors recognizing -cell specific peptides are enriched in pancreatic islets of T1D patients. Environmental stress causes -cells to upregulate MHC and to express IL-15 and IL-15RA. (Herold 2024 Nat Rev Immunol. PMID 38308004). It is estimated that 64,000 p...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBRX_OUT_27 [2025-04-16 16:18:02 -0400] 7377 Bytes | 2098 tokens | Cum: 6603 tkns (82.54% of 8k)
==========================================================================

This is our set of metrics for Forte Biosciences.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 76,964 | Perf Month: 32.00% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 36.69K | Perf Quarter: -56.00% | Short Float: 2.22% | ROE: -80.82% |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 2.10 | Index: - | Short Ratio: 3.22 | ROI: -67.60% |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 52.02 | Market Cap: 47.79M | Short Interest: 0.12M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 1.07 | Shs Outstand: 6.39M | Beta: 2.87 | EPS Surprise: 256.59% |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: 6.55% | Shs Float: 5.32M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -10.30% | Inst Own: 67.12% | Sales past 5Y: 0.00% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: -34.04% | Insider Own: 19.16% | Employees: 14 | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 27.37% | Insider Trans: 1.82% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by Forte Biosciences officers or majority shareholders (if available).

Inside Trans: Forte Biosciences, Inc. (FBRX) by Riley Antony A (CHIEF FINANCIAL OFFICER) on 2025-04-01
- Common Stock: 375 shares at $0 (D)
- Common Stock: 154 shares at $7.43 (D)
- Restricted Stock Units: 375 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Wagner Paul A. (SEE REMARKS) on 2025-04-01
- Common Stock: 1250 shares at $0 (D)
- Common Stock: 18 shares at $7.43 (D)
- Restricted Stock Units: 1250 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Kapoor Shivpreet Singh (Unknown Title) on 2025-03-20
- Stock Option (right to buy): 31000 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Wagner Paul A. (SEE REMARKS) on 2025-03-20
- Stock Option (right to buy): 920000 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by VINCENT RICHARD G (Unknown Title) on 2025-03-20
- Stock Option (right to buy): 31000 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Kornfeld Steven (Unknown Title) on 2025-03-20
- Stock Option (right to buy): 31000 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Riley Antony A (CHIEF FINANCIAL OFFICER) on 2025-03-20
- Stock Option (right to buy): 323000 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Brun Scott C. (Unknown Title) on 2025-03-20
- Stock Option (right to buy): 31000 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by GRYSKA DAVID W (Unknown Title) on 2025-03-20
- Stock Option (right to buy): 31000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1314000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -35478000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.26
Average Volume: 51752.61
30-Day High: 8.51
30-Day Low: 5.25

[Detailed Financials: TTM 2024]
- Total Assets: $61,561,000.0
- Total Liabilities: $9,081,000.0
- Total Equity: $52,480,000.0
- Current Assets: $61,346,000.0
- Current Liabilities: $9,081,000.0

[Income Statement: TTM 2024]
- Revenue: $1,314,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -12.17

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-14,881,000.0

[Detailed Financials: FY 2024]
- Total Assets: $61,561,000.0
- Total Liabilities: $9,081,000.0
- Total Equity: $52,480,000.0
- Current Assets: $61,346,000.0
- Current Liabilities: $9,081,000.0

[Income Statement: FY 2024]
- Revenue: $1,314,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -12.17

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-14,881,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Forte Biosciences (FBRX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Forte Biosciences.

2) MARKET_SCORE[]
This conversation was initiated because FBRX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for FBRX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, FBRX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect FBRX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Forte Biosciences.

11) ETHICAL_RATING[]
Rate Forte Biosciences’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Forte Biosciences.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

FBRX_IN_29 [2025-04-16 16:18:03 -0400] 126 Bytes | 29 tokens | Cum: 6835 tkns (85.44% of 8k)
==========================================================================

====================================
[2025-04-16 16:18:03] # Analysis Completed
Elapsed Time: 23.04 seconds